FORSTEO Receives Approval For Glucocorticoid-Induced Osteoporosis Treatment
European Commission has approved Eli Lilly and Company's new indication for FORSTEO(R) (teriparatide [rDNA origin] injection) for the treatment of osteoporosis associated with sustained, systemic glucocorticoid therapy in women and men at increased risk for fracture. This approval follows the initial positive opinion issued in February by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA).
Teriparatide stimulates new bone formation by increasing the number and action of bone-building cells called osteoblasts. Teriparatide, originally authorized for marketing in 2003 for the treatment of osteoporosis in postmenopausal women at high risk for fracture, received an expanded indication for the treatment of osteoporosis in men at increased risk for fracture in 2007.
"Chronic glucocorticoid therapy is the most common cause of secondary osteoporosis, often leading to bone loss and an increased risk for fracture," said Gwen Krivi, Ph.D., vice president of Lilly Research Laboratories. "We are pleased with the European Commission's decision to approve teriparatide for this new use."
Glucocorticoid-induced osteoporosis, or GIOP, is bone loss associated with chronic use of glucocorticoid medications. These medications are often prescribed for inflammatory conditions, such as rheumatoid arthritis and obstructive pulmonary disease. Globally, an estimated one to three percent of adults over the age of 50 use glucocorticoids.
"Up to 50 percent of individuals on chronic glucocorticoid therapy will develop bone loss leading to an osteoporotic fracture," said Dr. Steven Boonen, professor of medicine at the Leuven University Centre for Metabolic Bone Diseases in Belgium. "This new indication for teriparatide provides physicians and patients with a new treatment option that builds bone."
The submission package to support the safety and efficacy profile of teriparatide included new data from the "Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis" study, which was published in the November 15, 2007 issue of the New England Journal of Medicine. This head-to- head comparative study showed that in patients with glucocorticoid-induced osteoporosis, teriparatide significantly increased lumbar spine bone mineral density (BMD) from baseline (7.2 percent) compared to alendronate (3.4 percent) at 18 months of therapy.
Information about Teriparatide
Teriparatide is the active fragment (1-34) of the human parathyroid hormone and acts to stimulate bone formation by directly affecting bone forming cells (osteoblasts), indirectly increasing the intestinal absorption of calcium and increasing the re-absorption of calcium and excretion of phosphate by the kidney. Teriparatide, marketed in the U.S. since 2002, was first approved in the E.U. in 2003 for the treatment of established osteoporosis in postmenopausal women who have an increased risk of fracture.
As part of drug testing, teriparatide was given to rats for a significant part of their lifetime. In these studies, teriparatide caused some rats to develop osteosarcoma, a bone cancer. Osteosarcoma in humans is a serious but very rare cancer. Osteosarcoma occurs in about four out of every million older adults each year. It is not known if humans treated with teriparatide also have a higher chance of getting osteosarcoma.
Teriparatide should be prescribed only to patients for whom the potential benefits are considered to outweigh the potential risk. The drug should not be prescribed for patients at increased baseline risk for osteosarcoma, including patients with Paget's disease of bone or unexplained elevations of alkaline phosphatase, children or growing adults, or those who have had prior external beam or implant radiation therapy involving the skeleton. Additionally, patients with bone metastases or a history of skeletal malignancies, and those with metabolic bone diseases other than osteoporosis, should not receive teriparatide. Patients with high levels of calcium in their blood should not receive teriparatide due to the possibility of increasing their blood levels of calcium.
In clinical trials, the most frequent treatment-related adverse events reported at the 20-microgram dose approved for marketing were mild, similar to placebo and generally did not require discontinuation of therapy. The most commonly reported adverse events in patients treated with teriparatide are nausea, pain in limb, headache and dizziness.